我要投票 科汉森Puractive在益生菌行业中的票数:391
· 外 推 电 报 ·
2025-08-24 18:23:53 星期日

【科汉森Puractive是哪个国家的品牌?】

科汉森Puractive是什么牌子?「科汉森Puractive」是瑞士赫尔达夫集团公司旗下著名品牌。该品牌发源于广东省广州市,在2001年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力科汉森Puractive品牌出海!将品牌入驻外推网,定制科汉森Puractive品牌推广信息,可以显著提高科汉森Puractive产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

丹麦科汉森,具备130多年菌种研究历史,是自有营养健康中心益生菌供应商,拥有世界上较大,生产能力强的菌种工厂。在全球5个国家的工厂拥有GMP, Kosher, ISO22000、FSSC22000等资质。

BB-12源自科汉森收集的乳品发酵剂,被美国FDA认为“GRAS”, 于2005年获得中国卫生部新资源证书,2011年11月中国卫生部正式批准用于婴幼儿食品。它具有出色的耐酸和耐胆汁功能,优良的肠道黏附能力,是目前临床研究较多的益生菌,研究涵盖早产儿到老年人的所有人群。研究表明BB-12对婴幼儿和孕妇具有特殊功效,对普通人群也有改善肠道功能、调节免疫等功效。

1874 年由丹麦药剂师Christian D.A. Hansen 创立,总部位于丹麦荷尔首姆市。2009年9月签署《联合国全球契约》,2010年3月,在丹麦纳斯达克 OMX 证券交易所上市交易。员工超过 2300 人,遍布 30 多个国家。公司在五大洲都建有生产设施,生产工厂平均每周要接受三次严格的检查。

公司每年将营业额的约6%用于研发,14%的公司员工从事研发工作,全球19个应用与研发中心,主要基础研发机构设在丹麦,每年与300多高等院校、研究院所等展开科研合作,是20多家国际科研协会和顾问委员会的成员。

产品类型包括酶、益生菌、天然色素,以及用于膳食补充剂、非处方药、婴儿配方奶粉和动物饲料行业的产品等。乳品发酵剂是科汉森公司较大的业务,占公司总销售额的三分之二。科汉森公司在丹麦首都哥本哈根建立了全球规模较大的乳品发酵剂工厂。目前,科汉森公司在法国、德国、美国和丹麦四国建立了发酵剂生产部门。在全球5个国家的工厂拥有GMP, Kosher, ISO22000、FSSC22000等资质。


英文翻译:Kohansen, Denmark, with a history of more than 130 years of strain research, is a probiotic supplier of its own nutrition and health center, and has a large strain factory with strong production capacity in the world. We have GMP, kosher, ISO22000, fssc22000 and other qualifications in 5 countries around the world. Bb-12 originated from the dairy fermentation agent collected by cohenson, which was considered as "gras" by the FDA of the United States. It obtained the new resource certificate from the Ministry of health of China in 2005, and was officially approved by the Ministry of health of China for infant food in November 2011. It has excellent acid and bile resistant function, excellent intestinal adhesion ability, and is a probiotic with more clinical research at present, covering all groups from premature infants to the elderly. The research shows that Bb-12 has special effects on infants and pregnant women, and also has the effects of improving intestinal function and regulating immunity for the general population. Founded in 1874 by Christian D.A. Hansen, a Danish pharmacist, headquartered in holsham, Denmark. The United Nations Global Compact was signed in September 2009 and listed on the NASDAQ OMX stock exchange in March 2010. More than 2300 employees in more than 30 countries. The company has production facilities on five continents, and the production plants are subject to strict inspection three times a week on average. The company devotes about 6% of its turnover to R & D every year, 14% of its employees are engaged in R & D, 19 application and R & D centers around the world, and its main basic R & D institutions are located in Denmark. It cooperates with more than 300 institutions of higher learning and research institutes every year, and is a member of more than 20 international scientific research associations and advisory committees. Product types include enzymes, probiotics, natural pigments, and products used in dietary supplements, over-the-counter drugs, infant formula and animal feed industries. Dairy starter is a large business of the company, accounting for two-thirds of the company's total sales. Kohansen has established a large-scale dairy starter factory in Copenhagen, Denmark. At present, the company has established fermentation agent production departments in France, Germany, the United States and Denmark. We have GMP, kosher, ISO22000, fssc22000 and other qualifications in 5 countries around the world.

本文链接: https://www.waitui.com/brand/4bf3de924.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

格林美:筹划发行H股股票并在香港联交所上市

36氪获悉,格林美发布公告,经充分研究论证,董事会同意公司发行H股股票并在香港联合交易所有限公司(简称“香港联交所”)主板挂牌上市。公司将充分考虑现有股东的利益和境内外资本市场的情况,在股东会决议有效期内(即经公司股东会审议通过之日起24个月或同意延长的其他期限)选择适当的时机和发行窗口完成本次发行上市。截至目前,公司正积极与相关中介机构就本次发行上市的相关工作进行商讨,除本次董事会、监事会审议通过的相关议案外,其他关于本次发行上市的具体细节尚未最终确定。

24分钟前

中信证券:预计未来中国前列腺癌RDC诊疗市场将超100亿元

36氪获悉,中信证券研报表示,创新核药RDC有望解决目前前列腺癌诊疗过程中检测负担大、疗效有限等未被满足临床需求,改变前列腺癌诊疗范式,实现诊疗一体化,提高患者依从性和生存期。目前中国尚无任何RDC上市,市场呈现蓝海状态,海外前列腺癌RDC诊疗产品在2021年上市,2024年市场已接近30亿美元,充分验证了其巨大的商业价值。中信证券认为中国有望复刻海外前列腺癌RDC诊疗市场发展路径,预计未来中国前列腺癌RDC诊疗市场将超100亿元,市场呈现高速增长状态。该行业关键点为核素、配体分子形态、生产配送能力,建议关注在上述条件具有优势的公司。

24分钟前

​锡业股份:上半年净利润10.62亿元,同比增长32.76%

36氪获悉,锡业股份披露2025年半年报,上半年实现营业收入210.93亿元,同比增长12.35%;归属于上市公司股东的净利润10.62亿元,同比增长32.76%;基本每股收益0.626元。

24分钟前

亚世光电:上半年净利润538.04万元,同比下降36.21%

36氪获悉,亚世光电披露2025年半年报,上半年实现营业收入4.32亿元,同比增长30.01%;归属于上市公司股东的净利润538.04万元,同比下降36.21%;基本每股收益0.0331元。

24分钟前

金螳螂:上半年净利润3.58亿元,同比增长3.95%

36氪获悉,金螳螂披露2025年半年报,上半年实现营业收入95.28亿元,同比增长2.49%;归属于上市公司股东的净利润3.58亿元,同比增长3.95%;基本每股收益0.1348元。

24分钟前

本页详细列出关于科汉森Puractive的品牌信息,含品牌所属公司介绍,科汉森Puractive所处行业的品牌地位及优势。
咨询